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Abstract
 
CD1c-mediated T cells are activated by a mycobacterial phospholipid antigen whose carbohy-
drate structure precisely corresponds to mammalian mannosyl 
 
 
 
-1-phosphodolichol (MPD),
but contains an unusual lipid moiety. Here, we show that this T cell antigen is a member of a
family of branched, alkane lipids that vary in length (C
 
30-34
 
) and are produced by medically impor-
tant mycobacteria such as 
 
M. tuberculosis
 
 and 
 
M. bovis
 
 Bacille-Calmette-Guerin. The alkane
moiety distinguished these mycobacterial lipid antigens from mammalian MPDs and was necessary
for activation of CD1c-restricted T cells, but could not be accounted for by any known lipid
biosynthetic pathway. Metabolic labeling and mass spectrometric analyses suggested a mechanism
for elongating lipids using alternating C
 
2
 
 and C
 
3
 
 units, rather than C
 
5
 
 isopentenyl pyrophosphate.
Inspection of the 
 
M. tuberculosis
 
 genome identified one candidate gene, 
 
pks12
 
, which was predicted
to encode the largest protein in 
 
M. tuberculosis
 
, consisting of 12 catalytic domains that correspond to
key steps in the proposed pathway. Genetic deletion and complementation showed that Pks12
was necessary for antigen production, but did not affect synthesis of true isoprenols. These
studies establish the genetic and enzymatic basis for a previously unknown type of polyketide,
designated mycoketide, which contains a lipidic pathogen-associated molecular pattern.
Key words: tuberculosis • CD1 antigens • polyketide synthase • polyisoprenyl phosphate 
monosaccharides • lipids
 
Introduction
 
Mycobacterium tuberculosis
 
 remains one of the world’s most
prevalent and harmful pathogens, having infected 1.7 billion
humans, one third of the world’s population. 
 
M. tuberculosis
 
causes tuberculosis based on its ability to infect and persist
in lysosomes of host phagocytes and persist for years or decades
in human hosts.
The interface with the host is an unusually thick, lipid-
laden cell wall composed of the plasma membrane, pepti-
doglycan, arabinogalactan complexed to an outer mem-
brane of long chain fatty acids known as mycolic acids, and
a layer of surface exposed glycolipids. Synthesis of the outer
layers of this structure requires the export of carbohydrate
and lipids through plasma membrane using membrane
channels such as MmpLs (1) and lipid carbohydrate trans-
porters such as phosphopolyprenols, which transport sugars
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by flipping from the inner to the outer leaflet of mem-
branes (2). Compared with eukaryotic cells and other bac-
teria, mycobacteria have an unusually diverse repertoire of
lipids, with 
 
 
 
6% of the 
 
M. tuberculosis
 
 genome encoding
lipid-modifying enzymes, including those that lead synthe-
sis of phthiocerols, mycolic acids, sulfolipids, and other lip-
ids that are not found in eubacteria or mammalian cells.
Because many of these mycobacteria-specific lipids play
specialized, nonredundant roles in cell wall function, small
molecule inhibitors of mycobacterial lipid synthesis, such as
isoniazid, are among the most effective and least toxic anti-
microbial drugs in clinical use.
The mycobacterial cell wall functions as an immunopro-
tective barrier against host mechanisms of recognition and
killing, but also sheds lipids that activate immune responses
via Toll-like receptors and antigen presentation by group 1
CD1 proteins: CD1a, CD1b, and CD1c. CD1 proteins are
expressed in complex with 
 
 
 
2-microglobulin on B cells,
Langerhans cells, and myeloid DCs, including those found
at the sites of mycobacterial infection (3, 4). Human CD1a,
CD1b, and CD1c proteins bind several types of mycobac-
terial lipids, including mycolates (5–7), lipoarabinomannan
(8), trehalose sulfolipids (9), dideoxymycobactin (10), and
mannosyl-
 
 
 
-1-phosphoisoprenoids (MPIs; reference 11).
The resulting CD1–lipid complexes traffic to the cell sur-
face, allowing direct contact of intracellularly derived
mycobacterial lipids with T cell antigen receptors of lipid-
reactive T cells. CD1-restricted T cells express antimicro-
bial proteins such as 
 
 
 
-interferon and granulysin, and they
have the ability to lyse mycobacteria-infected target cells in
vitro (12, 13). In addition, human CD1-restricted T cells
recognizing mannosyl-
 
 
 
1-phospholipids (11), mycolyl gly-
colipids (14), and sulfotrehalose (9) can be detected in the
bloodstream of human patients acutely infected with 
 
M. tu-
berculosis
 
, but not healthy control subjects, indicating that T
cell recognition of mycobacterial cell wall lipids occurs
during the natural history of tuberculosis infections.
To date, the only known microbial lipid presented by
CD1c is an MPI antigen with an unusual structure that was
isolated from 
 
Mycobacterium avium
 
 (11). This lipid is of in-
terest in understanding the molecular basis of T cell dis-
crimination between self and foreign lipid structures be-
cause it contains a mannosyl-
 
 
 
-1-phosphate moiety that is
identical to those found in mannosyl-
 
 
 
-1-phosphodoli-
chols (MPDs) from mammalian cells. However, the lipid
portion of the MPI antigen is composed of an unusual 4, 8,
12, 16, 20-pentamethylpentacosyl unit, which has a fully
saturated backbone and short length (C
 
30
 
) compared with
polyunsaturated C
 
95
 
 polyisoprenols found in mammalian
cells. These observations suggested that the unusual
lipid moiety might be the key chemical element that al-
lows CD1c-restricted T cells to distinguish foreign MPIs
from self-MPDs, and thereby detect cellular infection (15).
However, it was unknown whether this or similar
phosphoglycolipids are produced by mycobacteria or
other pathogens of medical significance. Furthermore, the
branched, fully saturated structure of the MPI lipid moiety
did not conform to the expected products of any known
fatty acyl, polyprenol, or polyketide biosynthetic pathway,
which led us to study the structural diversity of naturally
occurring antigens, as well as the genes and biosynthetic
mechanisms involved in their production.
We found that antigenic MPIs were made by mycobac-
terial strains, which are capable of growth in human cells,
but were not detected in rapidly growing saprophytic my-
cobacteria or nonmycobacterial pathogens. Mass spectro-
metric analysis of MPIs revealed that they are a chemically
diverse family of structurally related mannosyl-
 
 
 
-1-phos-
pholipids with C
 
30–34
 
 alkane chains. Although a repeating
motif of C
 
5
 
 unit initially suggested that the lipid might be
made from isopentenyl pyrophosphate (IPP) using a modi-
fied polyisoprenol mechanism, variations in the expected
length and methyl branching patterns could not be ex-
plained by this model. Structural variations among natural
lipids and labeling studies suggested a hypothetical mecha-
nism for production of the isoprene-like alkyl backbone via
malonyl (C
 
2
 
) and methylmalonyl (C
 
3
 
) units and polyketide
synthases (PKSs). This led us to target 
 
pks12
 
 for knockout
in 
 
M. tuberculosis
 
 and 
 
Mycobacterium bovis
 
 Bacille-Calmette-
Guerin (BCG), which was found to be necessary for MPI
production and the CD1c-mediated T cell response. These
studies establish the genetic and enzymatic basis for a previ-
ously unknown lipid biosynthetic pathway leading to the
production of an antigenic mycobacterial polyketide, des-
ignated mycoketide.
 
Materials and Methods
 
Bacteria. M.  tuberculosis
 
 H37Rv and H37Ra were provided
by P. Brennan (Colorado State University, Fort Collins, CO). 
 
M.
avium
 
 serovar 4 was provided by H. Remold (Harvard Medical
School, Boston, MA). 
 
Escherichia coli
 
 was provided by H.
Band  (Northwestern University, Evanston, IL). 
 
M. tuberculosis
 
CDC1551 and 
 
Mycobacterium
 
 
 
smegmatis
 
 607 were obtained from
Center for Disease Control and Prevention. 
 
M. bovis
 
 BCG Pas-
teur, 
 
Leishmania niger
 
, 
 
Leishmania tropicana
 
, 
 
Mycobacterium phlei
 
, 
 
My-
cobacterium fallax
 
, 
 
Rhodocccus equi
 
, 
 
Nocardia farcinica
 
, 
 
Saccharomyces
pombe
 
, 
 
Candida albicans
 
, and 
 
Aspergillus niger
 
 were purchased from
American Type Culture Collection. 
 
M. tuberculosis
 
 H37Rv and
CDC1551 strains and 
 
M. bovis
 
 BCG were maintained on Middle-
brook 7H10 plates supplemented with oleic acid–albumin–dex-
trose complex. For liquid culture, a single colony was inoculated
in Middlebrook 7H9 media with 0.2% glycerol supplemented
with 10% albumin–dextrose and grown to mid-log phase. For la-
beling, bacteria were grown to an optical density of 0.4 at 600 nm
(OD
 
600
 
), changed to Proskauer-Beck medium for 1 d of growth,
treated with 1[
 
13
 
C]-sodium propionate or propionate (2 mM), and
further cultured for 3 d (OD
 
600
 
 
 
 
 
 0.9) before harvesting.
 
Cellular Assays.
 
Monocyte-derived DCs were prepared from
human PBMCs by centrifugation over Ficoll-Hypaque, adher-
ence to plastic, and treatment with 300 U/ml granulocyte/
monocyte-colony stimulating factor and 400 U/ml IL-4 for 72 h,
followed by 
 
 
 
-irradiation (5,000 rad) as described previously (16).
CD1c-restricted, MPI-reactive T cells (CD8-1; references 11,
17) were tested for IL-2 release using the HT-2 bioassay as de-
scribed previously (7). In brief, 5 
 
 
 
 10
 
4
 
 CD8-1 T cells and 5 
 
 
 
10
 
4
 
 
 
 
 
-irradiated monocyte-derived DCs were incubated in 200 
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L of T cell media for 24 h after which 50 
 
 
 
l of culture superna-
tant was transferred to wells containing 100 
 
 
 
l of the media and
10
 
4
 
 IL-2–dependent HT-2 cells, which were cultured for 24 h
before adding 1 
 
 
 
Ci [
 
3
 
H]thymidine for an additional 6 h of cul-
ture, followed by harvesting and counting 
 
 
 
 emissions. Assays
were done in triplicate and reported as the mean 
 
 
 
 standard de-
viation. For cytolysis, 10
 
6
 
 C1R lymphoblastoid cells transfected
with the vector pSR
 
 
 
-NEO containing the cDNAs encoding
human CD1a, CD1b, CD1c, and CD1d were labeled with 
 
51
 
Cr
in media (1 mCi/ml) with or without 
 
M. avium
 
 MPI overnight,
washed, and added at 2,000 cells per well to a 96-well plate.
CD8-1 T cells were added at an effector:target ratio of 20:1 for
4 h before measuring the 
 
51
 
Cr release in supernatants by scintilla-
tion counting and expressed as percent lysis compared with that
found in wells treated with detergent (2% NP-40).
 
Deletion and Complementation of pks12 Gene in M. tuberculosis
and BCG.
 
The 
 
pks12
 
 gene was deleted by specialized transduc-
tion as described previously (18). For genetic manipulations of
mycobacteria, 75 
 
 
 
g/ml hygromycin or 20 
 
 
 
g/ml kanamycin was
used for selection of transformants or transductants, whereas 150
 
 
 
g/ml hygromycin or 40 
 
 
 
g/ml kanamycin was used for selecting
 
E. coli
 
 HB101 transformants. To generate an allelic exchange sub-
strate for gene replacement, chromosomal sequences flanking 
 
M.
tuberculosis
 
 H37Rv 
 
pks12
 
 (Rv2048c) were PCR amplified from
 
M. tuberculosis
 
 H37Rv genomic DNA. Primers PKS12-1, 5
 
 
 
-ATC-
ACTAGTGTTGCGGTCGGTCTCATAG-3
 
 
 
, and PKS12-2,
5
 
 
 
-ATCAGATCTGCGCTCCAGCAACGCACG-3
 
 
 
, which con-
tained a SpeI and a BglII site, respectively, were used to amplify
a 1,016-bp fragment containing upstream flanking sequences.
Primers PKS12-3, 5
 
 
 
-CAATCTAGACAGGACCCGGCGTTG-
GCG-3
 
 
 
, and PKS12-4, 5
 
 
 
-TATCTTAAGTCTGGGCCGGC-
CAATCTG-3
 
 , which contained XbaI and AflII sites, respec-
tively, were used to amplify a 1,019-bp fragment containing
downstream flanking sequences. After cloning in pCR2.1-TOPO
(Invitrogen and Life Technologies) and sequencing, the cloned
fragments were excised using the introduced restriction sites and
cloned into the allelic exchange plasmid vector pJSC347. The re-
sultant plasmid p pks12 was cloned into a conditionally replicat-
ing shuttle plasmid phAE159 (increased cloning capacity, but sim-
ilar to phAE87; unpublished data) as described before (18), to
generate the specialized transduction phage phAE pks12. M. tu-
berculosis H37Rv, M. tuberculosis CDC1551, and M. bovis BCG
were transduced with phAE pks12 as described previously (18)
and hygromycin-resistant (HygR) colonies were screened by
Southern blot, using flanking sequences as probes to detect re-
placement of the pks12 ORF by the hyg cassette. One positive
clone of each strain was chosen for further work, and these were
designated as mc24701 for H37Rv  pks12, mc24702 for CDC-
1551  pks12, and mc24703 for BCG  pks12.
For complementation, a genomic DNA fragment (bp 2277324–
2322018) containing M. tuberculosis pks12 was excised from cosmid
pYUB2212 (HygR) by PacI digestion, and ligated into PacI-
digested, single copy integrative cosmid vector pJK93 (kanamy-
cin resistant; unpublished data), packaged into empty   phage
particles and transduced into E. coli HB101, to generate the kana-
mycin-resistant (KanR) complementing cosmid pYUB2410. Cosmid
DNA obtained from KanR HB101 colonies was electroporated
(19) into H37Rv  pks12, and HygR KanR transformants were
analyzed by Southern blot to confirm chromosomal integration
of pYUB2410.
Lipids and Lipid Antigens.  Bacteria harvested at mid-log
phase or cells were extracted at 5 mg/ml in chloroform:methanol
(C/M) (2:1, vol/vol) for 1 h at room temperature followed by
centrifugation (2,000 g) and removal of supernatants. The pellet
was reextracted in C/M (1:1, vol/vol) and C/M (1:2, vol/vol),
and all three supernatants were pooled to give “total lipids.” For
purification of MPI compounds, total lipids ( 50 mg) were ap-
plied to a silica gel column (23 ml of bed volume; Alltech), equil-
ibrated with chloroform, and washed with 40 ml of chloroform,
40 ml of acetone, and 50 ml of methanol. MPI antigens were re-
covered solely in the methanol eluates, which were further frac-
tionated by TLC using a silica gel G plate (Analtech Inc.) with a
solvent system of chloroform:methanol:water:ammonium hy-
droxide (60:35:7.2:0.8, vol/vol/vol/vol).
The lipid fraction with T cell activation activity was extracted
with C/M (1:1, vol/vol) from the gel and subjected to further
separation by HPLC with a Monochrome Diol column (46
mm   250 mm, 3  m; Varian Inc.) and coupled on-line to a
LCQ Advantage ion-trap mass spectrometer (ThermoElectron)
equipped with an electrospray ionization (ESI) source. Mobile
phase A was hexane:isopropanol (60:40, vol/vol) containing
0.1% (vol/vol) formic acid, 0.05% (vol/vol) ammonium hydrox-
ide, and 0.05% (vol/vol) triethylamine. Mobile phase B was
methanol containing 0.1% (vol/vol) formic acid, 0.05% (vol/vol)
ammonium hydroxide, and 0.05% (vol/vol) triethylamine. Using
a flow rate of 0.7 ml/min and the column temperature of 25 C,
separation was obtained by using a binary gradient starting at 5%
mobile phase B, linearly increasing to 15% B in 6 min and held at
15% B for 10 min, linearly increasing to 95% B in 8 min, held at
95% mobile phase B for 6 min and finally back to 5% B in 2 min.
The electrospray source was modified by using narrow stainless
steel tubing (127  m OD, 51  m ID; Small Parts Inc.) and was
operated at 1.9 kV. The heated capillary inlet was operated at
220 C. The HPLC effluent was split using fused silica tubing and
a micro-Tee union (Upchurch Scientific) to allow fraction col-
lection. This method allowed removal of phosphatidylinositol
and yielded MPI compounds judged as pure based on total ion
current profiles and ESI-mass spectrometry (MS) using nano-
spray. To separate MPI homologues with differing alkyl back-
bones, reverse phase HPLC with a Vydac C8 reverse phase
column (46 mm   250 mm, 3  m; Grace Vydac) was used.
Compounds were eluted with isopropanol:methanol:acetonitrile:
hexane:water (37:30:18:3:12, vol/vol/vol/vol/vol) containing 6
mM ammonium acetate.
The MPI compounds collected during the aforementioned
LC-MS separation were dried under nitrogen gas, dissolved in
chloroform:isopropanol:water (5:75:20, vol/vol/vol) containing
20 mM sodium acetate, and analyzed by MS/MS using both low
and high energy collisionally induced dissociation (CID) to pro-
duce product ions. Low-energy CID-MS/MS was performed on
the ion-trap mass spectrometer equipped with a nanoelectrospray
ion source (JA Hill, Instrument Services, Inc.). The spray voltage
and capillary temperature were set to 0.8 kV and 215 C, respec-
tively. Collision energy was 30–40% of maximum and the trap-
ping of product ions were performed with a q value of 0.25.
High-energy CID was performed using a double focusing
magnetic sector mass spectrometer (MStation; JEOL) which was
operated at 5 kV in the linked scan mode using helium leaked
into the collision cell (first field free region) at a sufficient pressure
to effect a 50% decrease in the parent beam.
Semi-synthetic mannosyl-1- -phosphodolichol with 95 car-
bon alkyl chain (C95 MPD) was synthesized from human hepatic
dolichol as described previously (11).
Online Supplemental Material.  Two-dimensional TLC analy-
ses of 14C-labeled lipids from M. tuberculosis H37Rv and M. tuber-
culosis CDC1551 are shown in Fig. S1. The lipids were devel-Mycoketide Produced by Pks12 1562
oped with petroleum ether:ethyl acetate (98:2, vol/vol) in the
first dimension and with petroleum ether:acetone (98:2, vol/vol)
in the second dimension to clearly separate phthiocerol dimyco-
cerosate (DIM) species. Online supplemental material is available
at http://www.jem.org/cgi/content/full/jem.20041429/DC1.
Results
Infectious Mycobacteria Produce a Family of Structurally Related
MPIs. A prior paper described an antigenic MPI from a
facultative human pathogen, M. avium (11). To determine
whether such unusual lipids are made by mycobacteria or
other pathogens that infect humans, we used a CD1c-
restricted, MPI-reactive T cell line named CD8-1 as a re-
porter line to screen total lipid preparations from several
species of mycobacteria, nonmycobacterial Actinomycetales,
Gram-positive bacteria, Gram-negative bacteria, protozoal
parasites, fungi, and human cells (Table I and reference 20)
(20). Initial studies using B lymphoblastoid target cells trans-
fected with various human CD1 isoforms confirmed that
the MPI-mediated recognition of target cells by CD8-1 was
absolutely dependent on expression of CD1c by antigen-
presenting cells and could not be mediated by other CD1
proteins (Fig. 1 A). T cells can detect  0.2 ng of purified
MPI, which under the conditions of this assay, represented
 1/100 of the level produced by BCG (Fig. 1 B). Among
the many types of bacterial and cellular organisms tested, T
cell activation was only seen in response to mycobacteria
(Table I). Among the mycobacterial strains tested, rapid
growing saprophytes such as M. phlei, M. fallax, and M.
smegmatis did not produce antigenic compounds at levels
detected by this assay. In contrast, all tested species or strains
that are capable of infecting human cells stimulated the re-
sponse at high titers, including M. avium, M. bovis BCG,
and several strains of M. tuberculosis. These results indicated
that antigenic MPIs are produced by mycobacteria includ-
Table I. MPI Compounds from Bacteria and Eukaryotic Cells
T cell
stimulationb
Fragment ions (MS/MS)e
Speciesa
[M-H]  c
(normalized
intensity)d
Lipid
length [M-H2O-H]  [M-C4H8O4-H] 
Alkyl
phosphate ion
Hexosyl
phosphate ion
M. tuberculosis   679 (10.7) C30 661 559 517 241
H37Rv 693 (3.9) C31 675 573 531
707 (100) C32 689 587 545 241
721 (2.4) C33 703 601 559
735 (5.9) C34 717 615 573 241
M. tuberculosis   679 (100) C30 661 559 517 241
CDC1551 707 (5.7) C32 689 587 545 241
M. bovis BCG   679 (10.6) C30
Pasteur 693 (6.1) C31
707 (100) C32 689 587 545 241
721 (5.6) C33
735 (5.0) C34
M. avium   679 (100) C30 661 559 517
693 (0.2) C31
707 (0.8) C32 689 587 545
721 (0.8) C33
M. tuberculosis   707f C32
H37Ra
Human
mononuclear cells
 
aTotal lipid extracts from M. smegmatis, M. phlei, M. fallax, R. equi, N. farcinica, S. aureus, E. coli, S. pombe, C. albicans, A. niger, L. donovani, and L.
tropicana did not stimulate T cells when tested as in Fig. 1 B.
bThe CDIc-mediated T cell activity in the crude lipid extracts were considered as ( ) when greater than twofold proliferation of T cells was seen in
response to total lipid fractions tested as in Fig. 1 B.
c[M-H]  ions of MPI compound detected by LC-MS analyses.
dIntensity of each MPI compound when the most abundant MS signal from each preparation is 100.
eDetected fragment ions by low energy CDI-MS analysis for a listed parent ion (left).
fSee reference 11.Matsunaga et al. 1563
ing a clinically important vaccine strain (BCG Pasteur) and a
natural isolate of M. tuberculosis from human patients (M. tu-
berculosis CDC1551).
In the MPI made by M. avium, the mannosyl- -1-phos-
phate group, which is predicted to protrude from the
CD1c antigen binding groove and function as part of the
epitope for responding T cells, is structurally identical to
phosphoglycan in MPDs found in all eukaryotic cells.
Therefore, we sought to determine whether MPI-reactive
T cells would cross-react with MPDs or other phospholip-
ids from human cells. CD8-1 was activated by total lipid
extracts from mycobacteria but not human cells, suggesting
that T cells might preferentially recognize mannosyl- -1-
phsopholipids with the unusual lipid moiety found in my-
cobacterial MPIs (Table I). Alternatively, the preferential
response to mycobacterial lipid extracts might simply have
resulted from lower absolute levels of mammalian MPDs in
cellular lipid extracts. To clarify this issue, we synthesized
MPD from human C95 dolichol and compared its potency
to the smaller, fully saturated C30 MPI from M. avium. Hu-
man C95 MPD showed faint or absent CD1c-mediated T
cell activation, in contrast with the potent activity of puri-
fied C30 MPI, and thus provided direct evidence that the
unusual lipid moiety found in mycobacterial MPI was re-
sponsible for its recognition by CD8-1 T cells (Fig. 1 C).
This prompted us to consider possible biosynthetic mecha-
nisms for producing this saturated, branched alkane lipid
that characterizes mycobacterial MPIs.
Structures of MPIs Are Not Consistent with Known Lipid
Biosynthetic Pathways. These lipid antigens were initially
described as being polyisoprene-like because, like true poly-
isoprenols made from serial condensation of IPP, they con-
tained a discernable repeating C5 structure with a methyl
branch at every fourth carbon on the alkyl chain. This sug-
gested a candidate mechanism whereby serial condensation of
IPP units might be followed by enzymatically catalyzed satu-
ration of the double bonds, as seen in biosynthesis of phytol
(21), a branched, saturated lipid found in plants (Fig. 2 A,
model 1). This simple model was attractive because it used
known enzymatic mechanisms and precursors and would be
viewed as an alternate form of polyisoprenol biosynthesis.
To evaluate this model, we first isolated highly purified
MPIs from M. tuberculosis and BCG and M. avium and used
collisional MS to identify naturally occurring variations in
chain length and branching patterns of the alkyl portion of
antigenic compounds. This was accomplished by develop-
ment of normal and reversed phase HPLC methods, which
generated purified preparations of MPIs and in most cases
achieved separation of individual molecular species of MPIs
based on C2H4 differences in chain length (Table I).
The MPI produced by M. avium predominantly yielded
an [M-H]  ion at m/z 679.6, corresponding to a mannosyl
phosphate with a C30 lipid tail (Table I). The predominant
MPI from M. tuberculosis H37Rv generated an [M-H]  ion
at m/z 707.6, which corresponded to an MPI with a C32
alkyl chain (Table I and Fig. 2 B). Analysis of phospholipids
from M. tuberculosis H37Rv, M. tuberculosis strain CDC1551,
and M. bovis BCG showed multiple molecular species of
homologous MPIs that varied from one another in incre-
ments of 14 u (m/z 679, m/z 693, m/z 707, m/z 721, and
m/z 735; Table I), suggesting that natural MPIs with C31,
C33, and C34 lipids also exist. This was confirmed by low
energy MS/MS analyses of M. tuberculosis H37Rv-derived
MPIs (Fig. 2 C), each of which yielded hexosyl phosphate
product ions at m/z 241.1, but differed in the size of the
alkyl phosphate moieties, which were between C30 and C34
in length. The same alkyl chain length distribution was seen
for BCG MPIs, and MPIs from M. tuberculosis CDC1551
showed diversity and did not differ in C5 increments (Table
I). Thus, naturally occurring MPIs represented an unexpect-
edly diverse family of structurally related lipids that differed
from one another in alkyl chain length by single CH2 incre-
ments, providing strong evidence against model 1 in which
condensation of IPP units would be produce lipid tails that
varied in length by C5 increments (Fig. 2 A).
High energy collisional dissociation MS using charge re-
mote fragmentation showed that the methyl branching pat-
terns on the alkane backbone of MPI did not correspond to
those predicted by model 1. Although both true isoprenols
and the MPI structures incorporate repeating C5 units with
a methyl branch at every fourth carbon, IPP is methylated
at the third ( ) carbon and would be expected to yield
Figure 1. CD1c-restricted T
cell responses for mycobacterial
phospholipids. (A) Human C1R
B lymphoblastoid cells trans-
fected with the indicated CD1
genes were pulsed with 10  g/
ml MPI, labeled with 51Cr, and
lysed by the CD8-1 T cell line
with an effecter target ratio of
20:1. (B) CD1c-mediated IL-2
production in response to DCs
treated with total lipid extracts
from mycobacteria was measured
using the HT-2 bioassay. (C)
CD1c-mediated IL-2 release was
measured in response to C30 MPI
compounds purified from M.
avium and C95 MPDs made from
human dolichol.Mycoketide Produced by Pks12 1564
 -methylated lipid moieties. However, the high energy
collisional fragmentation of the MPI from M. tuberculosis
(Fig. 2 D) yielded fragment ions at m/z 327, 397, 467, 537,
and 607, which correspond to cleavage products distal to
each methyl branch, and fragment ions were not seen at m/z
313, 383, 453, 523, and 593 as expected for methyl branches
at the  -C and every fourth carbon thereafter (Fig. 2 D, ar-
rows), similar to the pattern previously seen with M. avium
MPI (11). Therefore, the observed methyl branches were
out of register compared with those expected from con-
densation of C5 IPP units.
An Alternate Model Using PKSs. This prompted us to
consider model 2, in which the repeating C5 units were
made by alternating addition of C2 and C3 units, which
would be supplied from malonate and methylmalonate, re-
spectively (Fig. 2 A). Although this mechanism had no di-
rect precedent, elongation in C5 increments could be
performed by a plausible mixed fatty acyl-polyketide
mechanism in which a carboxylate primer of varying length
is coupled to the repeating C5 motif, which actually repre-
sents repeating cycles of C2 and C3 unit condensation. The
final carboxylate moiety would be reduced to an alcohol
and phosphorylated to yield a substrate for glycosylation.
This biosynthetic mechanism was considered plausible be-
cause mycobacteria were known to use PKSs to produce
polymethylated alkane lipids of various sorts, including
Figure 2. MPI species from M. tuberculosis H37Rv and selective labeling of the alkyl backbone of C32 MPI. (A) Model 1 is based on sequential conden-
sation of IPP moieties to form a polyisoprenol, which is subsequently acted upon an enzyme with saturase activity. In Model 2, the alkyl backbone is
primed by a fatty acyl group and extended by alternating condensation of malonate and methylmalonate in repeated cycles to yield a carboxylic acid
product. (B and C) An MPI antigen purified from M. tuberculosis H37Rv was subjected to ESI-MS in the negative mode. The major product, C32 MPI
(m/z 707.6), differed in size from the major product from M. avium (m/z 707.6; Table I), and lower abundance ions at m/z 679.6, 693.7, 721.6, and
735.6 were also seen, providing evidence for structural diversity of these natural compounds. Low energy CID-MS/MS for compounds of m/z 679.6,
707.6, and 735.6 generated fragments ions corresponding to a hexosyl phosphate ion (m/z 241) as well as saturated alkyl phosphates corresponding to C30
(m/z 517), C32 (m/z 545), and C34 (m/z 573), respectively, demonstrating that the size variations are accounted for by differences in sizes of the alkyl
moiety. (D) High energy CID-MS/MS (double-focusing magnetic sector mass spectrometer) for C32 MPI shows a series of ions at 14-u or 28-u intervals.
The 28-u intervals (arrows) correspond to methyl branches at C4, C8, C12, C16, and C20. (E) M. tuberculosis H37Rv was grown in the presence of 13C-
labeled propionate or nonlabeled propionate and subjected to lipid extraction and analysis using a quadruple ion trap mass spectrometer. Compared with
unlabeled MPI, the mass shift of the main product from m/z 707.6 to 713.6 corresponded to the incorporation of six C3 units in each molecule. MS/MS
spectra of m/z 713.6 shows that the alkyl phosphate fragment (m/z 551.5) was shifted by six mass units compared with the corresponding fragment from
unlabeled C32 MPI (m/z 545.5; panel C), indicating that as many as six C3 units are incorporated into the alkyl chain.Matsunaga et al. 1565
phthiocerol and mycocerosic acid (22). Importantly, this
model could account for the unusual structures of natural
MPIs because, unlike IPP, all precursors are saturated. Fur-
thermore, the C2 and C3 condensation product would con-
tain a  -methyl branch, and the C1 increments in chain
length could come from varying fatty acyl primers, so that
this model could account for all of the observed features of
the natural alkane lipids isolated from M. avium, BCG, and
M. tuberculosis.
Although isoprenoid biosynthesis involves assembly of
IPP units made from acetate or glyceraldehyde phosphate
and pyruvate, a prediction of model 2 is that the alkyl
backbone is made by assembly of up to five methyl-
malonate units. To test this model, we biosynthetically la-
beled M. tuberculosis lipids by growth in media formulated
with  13C-propionate, which is a precursor of methyl-
malonate in bacteria. Labeled and unlabeled MPIs were an-
alyzed using ESI-MS (Fig. 2 E). Negative mode mass spectra
of C32 MPI from bacteria grown in control media showed
a predominant ion [M-H]  at 707.6 with adjacent isotope
peaks whose abundance corresponded to the expected ra-
tios of naturally occurring 13C and 2H. In contrast, MPI
from M. tuberculosis grown with 13C-labeled propionate
showed two predominant ion clusters near m/z 707.6 and
713.6. Isotopically labeled ions were shifted by  6 u, con-
sistent with incorporation of labeled carbon at the site of
one C3 primer from propionate and five C3 elongation
units from methylmalonate per molecule.
To confirm that the ion at m/z 713.6 was indeed MPI,
we performed MS/MS analysis of this labeled molecule
(Fig. 2 E) in comparison with unlabeled MPI from the
same species (Fig. 2 B). As expected, decomposition of the
ion at 713.6 detected fragments corresponding to mannose
phosphate (m/z 241.1), alkyl phosphate (m/z 551.5), and
a through-ring cleavage product, [M-C4H8O4-H]  (m/z
593.6). Compared with the corresponding fragments from
unlabeled MPI, the 6-u mass shift of all products contain-
ing the alkyl unit provided direct evidence that six 13C la-
bels were incorporated into the branched lipid. Conversely,
the lack of mass shift in the mannosyl phosphate product
(m/z 241.1) provided evidence that the pulse labeling
method used here did not diffusely label distantly down-
stream products through multiple biochemical conversions.
Thus, the unusual lipid unit was produced from propionate
precursors and was incorporated as predicted by model 2.
PKS12 Is Necessary for Production of Antigenic MPIs. The
natural MPI structures suggested a polyketide rather than
polyisoprenoid mechanism of biosynthesis, so we sought to
identify the mycobacterial genes, which performed MPI
synthesis. We considered whether the detailed biosynthetic
predictions of model 2 might support a targeted, reverse
genetics approach in which the responsible genes might be
deduced based on the necessary enzymatic activities that
would be required to carry out model 2. By searching the
TubercuList database (http://genolist.pasteur.fr/TubercuList;
reference 23), we found 23 genes that were annotated
as likely having PKS activities in the M. tuberculosis ge-
nome, though their functions remain largely undeter-
mined. Because the MPI backbone is completely saturated
and lacks hydroxyl or keto groups, a complete set of fatty
acid synthase (FAS)-like catalytic domains would be neces-
sary to catalyze acyltransfer, ketosynthesis, ketoreduction,
dehydration, and enoyl reduction. Furthermore, because
the C2 and C3 units were incorporated strictly in an alter-
Figure 3. Deletion and com-
plementation of pks12. (A) South-
ern blot of StuI-digested genomic
DNA from M. tuberculosis H37Rv,
M. tuberculosis CDC1551, and
M. bovis BCG, and the respective
pks12 deletion mutant strains
H37Rv   pks12, CDC1551
 pks12, and BCG  pks12. The
adjoining map shows the chromo-
somal regions of BCG, M. tubercu-
losis H37Rv, and H37Rv  pks12.
res,    resolvase site; hyg, hygro-
mycin resistance gene. The re-
gions used as probes are indicated
( - ). (B–D) Total lipid extracts
from parental, pks12-deficient
strains, and strains complemented
with the pYUB2410 vector con-
taining  pks12 were tested for
their ability to stimulate IL-2
production of the CD1c-restricted
T cell line, CD8-1, using DCs as
antigen-presenting cells.Mycoketide Produced by Pks12 1566
nating manner (rather than at random), we reasoned that
two-sets of FAS would likely be required, one for C2 units
and one for C3 units. Among the 23 putative PKSs made
by M. tuberculosis, pks12, the largest open reading frame in
the genome, was a good candidate because it was predicted
to encode an extremely large polypeptide with 12 enzy-
matic domains, including two complete sets of FAS-like
catalytic domains. Moreover, a recent paper on substrate
specificity of the acyltransferase (AT) domains of pks12 pre-
dicted that one of them is specific for malonyl-CoA and
the other is for methylmalonyl-CoA (24), consistent with
model 2 (Fig. 2 A). In addition, there was evidence for re-
tention of pks12 genes in the M. tuberculosis CDC1551
strain and BCG, two species that were known to make an-
tigenic MPIs (Table I).
To directly test this hypothesis, we used homologous
recombination to disrupt pks12 genes in M. tuberculosis
H37Rv, BCG, and M. tuberculosis CDC1551 and measured
the ability of mutants to activate CD1c-restricted T cells.
Allelic exchange of pks12 with a hygromycin resistance
gene (hyg) was performed using specialized transduction
(18) with a conditionally replicating phage carrying the ho-
mologous recombination substrate. Hygromycin-resistant
colonies obtained after transduction were analyzed by
Southern blot to detect replacement of pks12 by hyg (Fig. 3
A). The left and right flanking DNA, used as probes, hy-
bridized with 6.083 kb and 8-kb StuI-digested bands in all
wild-type M. tuberculosis strains, and 6.083-kb and 12.445-
kb StuI bands in BCG, and with an 8.09-kb band in all
mutant strains, consistent with what was expected from a
bonafide gene replacement. Expected band patterns were
also observed in Southern blots of KpnI-digested genomic
DNA (unpublished data), confirming the results. Allelic ex-
change resulted in the replacement of bp 97–12,360 of
pks12 by hyg, thus removing sequences corresponding to all
the twelve domains of the PKS. The three pks12-deleted
mutant strains of H37Rv, CDC1551, and BCG (mc24701,
mc24702, and mc24703, respectively) are referred to as
H37Rv  pks12, CDC1551  pks12, and BCG  pks12. As
shown in Fig. 3 (B–D), deletion of pks12 genes in each of
these three strains completely abolished the ability of all
three strains to activate CD1c-restricted T cells. Con-
versely, introduction of pks12 into H37Rv  pks12 restored
the T cell response to levels seen in wild-type bacteria (Fig.
3 B). This restoration of MPI production was observed in
two independent pks12-complemented H37Rv clones (un-
published data).
In parallel, LC-MS methods were used to analyze MPIs
and related lipids in phospholipid extracts of M. tuberculosis
H37Rv and H37Rv  pks12. Under conditions in which
parental and mutant strains gave similar overall phospho-
lipid profiles as determined by total ion currents in LC-MS
detection, mass chromatograms targeting the molecular
ions (m/z 707–708) of the MPI gave a strong signal in the
parental M. tuberculosis strain at the expected retention time
(10 min) but no signal in H37Rv  pks12 (Fig. 4 A). Fur-
thermore, the mass spectra at the retention time of 10 min
from the parental and the mutant strains clearly show that
MPIs are only found in the parental strain (Fig. 4 B). A
mass spectral analysis for lipids from the pks12-comple-
mented strain confirmed restoration of MPI production
(unpublished data). Together, these data provide strong
biochemical and immunological evidence that the PKSs
encoded by pks12 is involved in MPI biosynthesis. In con-
trast with an earlier paper that suggested that an H37Rv
Figure 4. MPI and polyprenol biosynthesis pathways function inde-
pendently. (A) Mass chromatograms of measured ions in the mass range
corresponding to MPI (m/z 707.0–708.0; bottom) were compared with
total ion chromatograms (top) in HPLC separation of phospholipids from
M. tuberculosis H37Rv parental strain and the  pks12 mutant. The total
ion current trace shows that total phospholipid pattern was not substan-
tially altered and confirms that similar amounts of lipids were analyzed for
the comparison of m/z 707–708 ions. (B) Mass spectra at the retention
time of 10 min in the chromatograms shown in A. The 100% relative
abundance of the y axis was adjusted to the same intensity in each mass
spectra from the parental and the mutant strains. (C) CDI-MS spectra of
phospholipids from the  pks12 mutant showed an ion of m/z 939.5,
which corresponded to the expected mass and collision products of a true
polyisoprenol phosphoglycolipid, mannosyl- -1-phosphopolyisoprenol (C50
MPP). The ions of m/z 921.6 and m/z 903.7 corresponded to ones,
which lost one or two water molecules from the parent ion and m/z
241.1 corresponded to a hexosyl phosphate ion.Matsunaga et al. 1567
pks12 mutant did not synthesize DIMs (25), TLC analysis
of total lipids (labeled with 14C-acetate or propionate) ex-
tracted from H37Rv  pks12 and CDC1551  pks12 re-
vealed presence of DIMs (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20041429/DC1).
Because Pks12 has the catalytic domains predicted to
make the alkyl backbone of MPIs, we favored the possibility
that Pks12 actually synthesizes this lipid, but there was some
possibility that this Pks12 functioned in some indirect way
to alter the synthesis of polyisoprenols. To test whether
Pks12 affects polyprenol biosynthesis, we sought to measure
a known product of polyisoprenol synthases, C50 mannosyl-
 -1-phosphopolyisoprenol (C50 MPP) in the M. tuberculosis
H37Rv  pks12 mutant (26). ESI-MS analysis revealed a
negative ion corresponding to the predicted [M-H]  of C50
MPP (m/z 939.5) in both the parental strain and mutant
strains, and MS/MS analysis confirmed that the m/z values
of its products matched the expected masses for hexose
phosphates and a polyunsaturated phosphodecaprenol (Fig.
4 C). Thus, deletion of the pks12 gene did not disrupt bio-
synthesis of a polyisoprenol compound, providing clear evi-
dence that polyketide and polyisoprenoid phospholipids are
made by independent mechanisms. Furthermore, the failure
of T cells to recognize phospholipids from this mutant (Fig.
3 B) indicated that mannosyl- -1-phospholipids with true
polyisoprenol lipid moieties do not substitute as potent anti-
gens for the T cell response.
Discussion
MPIs were originally identified as scarce, but immuno-
logically potent, phospholipid components of the myco-
bacterial cell wall that trigger CD1c-mediated human T
cell responses (11). The mannosyl- -1-phosphate head
group, along with the repeating C5 structure, provided an
obvious structural homology of these antigenic phospho-
lipids with evolutionarily conserved mannosyl phospho-
polyprenols that function as carbohydrate carriers (15). Here,
we provide structural, biosynthetic, and genetic evidence
that the repeating C5 units found in these lipids are made
by Pks12 from methylmalonate and malonate precursors.
This represents a new type of lipid synthesis mechanism
that leads to the production of alkane lipids that structurally
mimic polyisoprenols but are made by a polyketide mech-
anism. Based on their mode of synthesis and their con-
served expression among infectious mycobacterial species,
the 4-, 8-, 12-, 16-, and 20-branched alkane lipids can
be simply referred to as mycoketides and the antigenic phos-
phoglycolipid forms as mannosyl- -1-phosphomycoketides
(MPMs).
Although fatty acid synthesis involves chain elongation
by repeated acyltransfer, ketosynthesis, ketoreduction, de-
hydration, and enoyl reduction of C2 units, polyketide bio-
synthesis can involve all, some, or none of these functional
group modifications. The AT modules of PKSs control
whether malonyl (C2), methylmalonyl (C3), or ethylmalo-
nyl (C4) enter into the elongation cycles, so that varied pre-
cursors and partial cycles allow PKSs to produce structur-
ally diverse lipid products. The pks12 gene is predicted to
encode a 430-kD protein, which is a typical type I PKS
with 12 contiguous, but separately functioning, enzymatic
domains. Although the function of the Pks12 has not been
extensively analyzed, a detailed comparison of the sequence
of pks12 to PKSs of known function had predicted that
Pks12 had two complete sets of FAS-like domains in which
substrate specificities of two AT domains were predicted to
be specific for malonate (C2) and methylmalonate (C3), re-
spectively (24). Thus, the overall domain organization of
this enzyme, with duplicate FAS modules and two differing
AT activities, is consistent with a mechanism of lipid elon-
gation involving the alternating insertion of one C2 and
one C3 units per cycle, as predicted by model 2 (Fig. 2 A).
The structures of mycoketides provide detailed informa-
tion that independently support this model and rule out
competing models based on polyisoprenol pathways in-
volving IPP. Instead of a  -methyl branch and an unsatu-
rated structure typical of IPP, the sequential condensation
of malonate and methylmalonate yields a C5 unit with fully
saturated,  -methyl units. Synthesis of mycoketides from
this basic unit is consistent with the detection of fully satu-
rated lipid moieties in all MPMs studied (Table I), the
 -methyl branches seen in M. avium (11) and M. tuberculosis
(Fig. 2 D), the incorporation of the expected number of
methylmalonyl units into the final MPM product (Fig. 2
E), and the precise positioning of 5 methyl branches at ev-
ery fourth carbon in MPMs analyzed from M. avium and
M. tuberculosis (Fig. 2 D). The incremental C1 differences in
length seen among different MPMs produced by the same
organism (Fig. 2 B) and species-specific differences in the
C30 (M. avium) or C32 (M. tuberculosis H37Rv and BCG)
can be explained by differences in the length of the carbox-
ylate primer. However, it is noted that primer selection is
not entirely understood and is somehow unusual because
fatty acids with an even number of carbons usually pre-
dominate, but the most abundant species of MPM appear
to use C5 (M. tuberculosis CDC1551 and M. avium) or C7
primers (M. tuberculosis H37Rv and H37Ra and BCG).
The production and linkage of carboxylate primers to poly-
ketides have not been directly established, but combina-
tional biosynthesis by FAS and PKS systems were recently
reported in mycobacteria, providing a precedent for this
type of a mixed FAS-PKS mechanism (27).
This new pathway for production of mycoketides and
the predicted steps by which mycoketides are converted
to phosphomycoketides are outlined in Fig. 5. The one
to one correspondence between the predicted enzymatic
functions of the 12 subunits of Pks12 with the biochemical
reactions need to produce mycoketide suggests that Pks12
may be sufficient for production of the mycoketide unit.
This lipid would have to undergo offloading from Pks12,
reduction, phosphorylation, and glycosylation by as yet
unknown mechanisms to produce the final MPM phos-
phoglycolipid antigen. An earlier paper demonstrated that
pks12-deleted mycobacteria lack DIM, a polyketide that
might be plausibly produced by this mechanism. However,
our data, which include analysis of pks12-complementedMycoketide Produced by Pks12 1568
strains, demonstrate that DIM is produced by pks12-defi-
cient M. tuberculosis. Because previous studies have reported
that loss of DIM leads to attenuation (28, 29), it is difficult
to determine whether the previously reported effects of
pks12 on mycobacterial growth in mice were due to DIM
loss, MPM loss, or both (25).
This complex biosynthesis pathway is energetically ex-
pensive, and is lacking in saprophytic mycobacteria, but is
conserved in all tested infectious mycobacteria, suggest-
ing that mycoketides play a functional role in intracellular
growth. In general, polyketides are not abundant structural
lipids with basic housekeeping functions, but instead are
secondary metabolites that function as antimicrobial com-
pounds, signaling molecules or other highly specialized
roles. Consistent with this, we found that MPMs are
present at low absolute levels, as they comprise  1 ppm of
the total weight of the cell wall (unpublished data). The
structural homology of MPM with MPDs that function in
transmembrane carbohydrate transport raises that possibility
that MPMs also function as lipid intermediates in mannose
transmembrane transport or transfer.
One function of MPMs is quite clear, as these lipids are
presented by CD1c proteins to human T cells and provide
a signal for the detection of intracellular mycobacteria dur-
ing tuberculosis infection (11). These results support this
idea by showing that MPMs are produced by mycobacteria
of medical importance, including the M. tuberculosis and
vaccine strains of BCG. The mycoketide portion of the an-
tigen is produced by a lipid biosynthetic pathway present in
mycobacterial pathogens, but is lacking in mammalian spe-
cies that express CD1c on their antigen-presenting cells.
Furthermore, the shorter chain length and saturated struc-
ture of mycoketides, in contrast with the homologous
mammalian polyisoprenols, represent two chemical ele-
ments that increase the potency of a CD1c-mediated T cell
response (Fig. 1 C).
T cell recognition of lipid antigens occurs after the lipid
portion of the antigen is inserted into an antigen-binding
groove on the distal surface of the CD1 protein. The
grooves of CD1d (30), CD1a (31), and CD1b (32) are op-
timized to accommodate lipid antigens of approximately
C40, C32, and C60 in length, respectively. Unlike CD1b,
which has small amino acid side chains at conserved posi-
tions on the floor of the groove, the CD1c sequence en-
codes amino acids with larger side chains like those seen in
CD1a and CD1d, so that the CD1c groove size may be
similar to that of CD1a and CD1d (32, 33). Thus, C95
mammalian MPDs are larger than any known CD1 groove,
and the smaller C30-34 mycoketide may be of the correct
size to fit within the CD1c groove. The discovery of the
mycoketide biosynthetic pathway in mycobacteria provides
insight into how the shorter, saturated lipid portion of my-
coketide represents a pathogen-associated molecular pat-
tern, which allows mycobacteria to be recognized as for-
eign by the human immune system (34).
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